The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

As per The Business Research Company’s Genetic Toxicology Global Market Report 2023, the genetic toxicology market is expected to show significant growth in the forecast period.

Market Overview

• Significant growth in recent years: The genetic toxicology testing market grew from $1.48 billion in 2023 to $1.63 billion in 2024, with a 10% CAGR.
• Projected expansion: By 2028, the market is expected to reach $2.4 billion, growing at a 10.2% CAGR.

Historical Growth Drivers

• Public health crises: Rising health concerns have fueled the demand for genetic toxicology testing.
• Globalization: Increased cross-border trade necessitates rigorous testing solutions.
• Personalized medicine: A focus on tailored healthcare has led to more genetic testing.
• Drug development: The growing number of drugs requires extensive genetic toxicity testing.

View More On The Genetic Toxicology Market Report 2024 – https://www.thebusinessresearchcompany.com/report/genetic-toxicology-testing-global-market-report

Future Growth Drivers

• Testing for novel foods: Rising concerns about food safety will drive demand for genetic toxicology testing.
• Environmental and health concerns: Increased awareness of environmental risks will boost the market.
• Regulatory scrutiny: Stricter regulations will lead to more rigorous testing protocols.
• In vitro methods: These methods are increasingly being adopted for their efficiency.
• High-throughput screening: The rise of these platforms will enhance testing capabilities.

Role of Personalized Medicine

• Demand surge: Personalized medicine, which tailors treatments to individual patients, is a significant growth driver.
• Genetic breakthroughs: Advances in genetics have fueled the rise of personalized medicine.
• FDA approvals: In 2023, the FDA approved 16 new personalized medicines, up from six in 2022.
• Impact on genetic toxicology: This testing provides critical data on genetic variability and treatment responses, supporting personalized medicine initiatives.

Major Market Players

• Key companies: F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, and others dominate the market.
• Focus on innovation: Companies are developing new drug screening platforms to enhance testing accuracy.

Innovations in Drug Screening

• Phenotypic drug screening: A method focusing on the effects of compounds in living organisms is revolutionizing the market.
• Creative Biogene’s zebrafish models: Launched in August 2022, these models support drug discovery and toxicology research, offering a platform to assess drug toxicity.

Strategic Acquisitions

• Charles River Laboratories and Vigene Biosciences: In June 2021, Charles River acquired Vigene Biosciences for $292.5 million, expanding its gene therapy capabilities.
• Focus on CDMO sectors: The acquisition bolsters Charles River’s presence in the cell and gene therapy contract development and manufacturing organization sectors.

Market Segmentation

• By Type: In Vitro, In Vivo.
• By Product: Services, Reagents and Consumables, Assays.
• By Application: Healthcare, Food, Cosmetics, Agriculture, and other industries.

Regional Insights

• North America: The largest market in 2023.
• Asia-Pacific: Expected to be the fastest-growing region during the forecast period.

Request A Sample Of The Global Genetic Toxicology Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=15574&type=smp